It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Supporting self-management is key in improving disease control, with technology increasingly utilised. We hypothesised the addition of telehealth support following assessment in an integrated respiratory clinic could reduce unscheduled healthcare visits in patients with asthma and COPD. Following treatment optimisation, exacerbation-prone participants or those with difficulty in self-management were offered telehealth support. This comprised automated twice-weekly telephone calls, with a specialist nurse triaging alerts. We performed a matched cohort study assessing additional benefits of the telehealth service, matching by: confirmed diagnosis, age, sex, FEV1 percent predicted, smoking status and ≥1 exacerbation in the last year. Thirty-four telehealth participants were matched to twenty-nine control participants. The telehealth cohort generated 165 alerts, with 29 participants raising at least one alert; 88 (53.5%) alerts received a call discussing self-management, of which 35 (21%) received definitive advice that may otherwise have required an unscheduled healthcare visit. There was a greater reduction in median exacerbation rate across both telehealth groups at 6 months post-intervention (1 to 0, p < 0.001) but not in control groups (0.5 to 0.0, p = 0.121). Similarly, there was a significant reduction in unscheduled GP visits across the telehealth groups (1.5 to 0.0, p < 0.001), but not the control groups (0.5 to 0.0, p = 0.115). These reductions led to cost-savings across all groups, but greater in the telehealth cohorts. The addition of telehealth support to exacerbation-prone patients with asthma or COPD, following comprehensive assessment and treatment optimisation, proved beneficial in reducing exacerbation frequency and unscheduled healthcare visits and thus leads to significant cost-savings for the NHS.
Clinical Trial Registration: ClinicalTrials.gov: NCT03096509
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Portsmouth Hospitals University NHS Trust, Portsmouth Technology Trials Unit, Portsmouth, UK (GRID:grid.418709.3) (ISNI:0000 0004 0456 1761)
2 Portsmouth Hospitals University NHS Trust, Portsmouth Technology Trials Unit, Portsmouth, UK (GRID:grid.418709.3) (ISNI:0000 0004 0456 1761); Portsmouth Hospitals University NHS Trust, Respiratory Medicine, Portsmouth, UK (GRID:grid.418709.3) (ISNI:0000 0004 0456 1761)
3 Bordon Medical Centre, Bordon, UK (GRID:grid.418709.3)
4 University of Portsmouth, Faculty of Science and Health, Portsmouth, UK (GRID:grid.4701.2) (ISNI:0000 0001 0728 6636)
5 Portsmouth Hospitals University NHS Trust, Portsmouth Technology Trials Unit, Portsmouth, UK (GRID:grid.418709.3) (ISNI:0000 0004 0456 1761); Portsmouth Hospitals University NHS Trust, Respiratory Medicine, Portsmouth, UK (GRID:grid.418709.3) (ISNI:0000 0004 0456 1761); University of Portsmouth, Faculty of Science and Health, Portsmouth, UK (GRID:grid.4701.2) (ISNI:0000 0001 0728 6636)